Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
CYP3A plays an important role in drug metabolism and, thus, can be a considerable liability for drug-drug interactions. Population pharmacokinetics may be an efficient tool for detecting such drug-drug interactions. Multiple models have been developed for midazolam, the typical probe substrate for C...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
08 August 2020
|
| In: |
Journal of pharmacokinetics and pharmacodynamics
Year: 2020, Volume: 47, Issue: 6, Pages: 527-542 |
| ISSN: | 1573-8744 |
| DOI: | 10.1007/s10928-020-09704-1 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s10928-020-09704-1
|
| Author Notes: | Sabrina T. Wiebe, Andreas D. Meid, Gerd Mikus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1779108338 | ||
| 003 | DE-627 | ||
| 005 | 20240415193236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211125s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10928-020-09704-1 |2 doi | |
| 035 | |a (DE-627)1779108338 | ||
| 035 | |a (DE-599)KXP1779108338 | ||
| 035 | |a (OCoLC)1295680212 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wiebe, Sabrina |e VerfasserIn |0 (DE-588)1219325988 |0 (DE-627)1735273597 |4 aut | |
| 245 | 1 | 0 | |a Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity |c Sabrina T. Wiebe, Andreas D. Meid, Gerd Mikus |
| 264 | 1 | |c 08 August 2020 | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.11.2021 | ||
| 520 | |a CYP3A plays an important role in drug metabolism and, thus, can be a considerable liability for drug-drug interactions. Population pharmacokinetics may be an efficient tool for detecting such drug-drug interactions. Multiple models have been developed for midazolam, the typical probe substrate for CYP3A activity, but no population pharmacokinetic models have been developed for use with inhibition or induction. The objective of the current analysis was to develop a composite parent-metabolite model for midazolam which could adequately describe CYP3A drug-drug interactions. As an exploratory objective, parameters were assessed for potential cut-points which may allow for determination of drug-drug interactions when a baseline profile is not available. The final interaction model adequately described midazolam and 1′-OH midazolam concentrations for constitutive, inhibited, and induced CYP3A activity. The model showed good internal and external validity, both with full profiles and limited sampling (2, 2.5, 3, and 4 h), and the model predicted parameters were congruent with values found in clinical studies. Assessment of potential cut-points for model predicted parameters to assess drug-drug interaction liability with a single profile suggested that midazolam clearance may reasonably be used to detect inhibition (4.82-16.4 L/h), induction (41.8-88.9 L/h), and no modulation (16.4-41.8 L/h), with sensitivities for potent inhibition and induction of 87.9% and 83.3%, respectively, and a specificity of 98.2% for no modulation. Thus, the current model and cut-points could provide efficient and accurate tools for drug-drug liability detection, both during drug development and in the clinic, following prospective validation in healthy volunteers and patient populations. | ||
| 700 | 1 | |a Meid, Andreas |d 1981- |e VerfasserIn |0 (DE-588)1076301991 |0 (DE-627)834660377 |0 (DE-576)445184582 |4 aut | |
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmacokinetics and pharmacodynamics |d Dordrecht [u.a.] : Springer Science + Business Media B.V., 2001 |g 47(2020), 6, Seite 527-542 |h Online-Ressource |w (DE-627)325570183 |w (DE-600)2037307-7 |w (DE-576)121466418 |x 1573-8744 |7 nnas |a Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity |
| 773 | 1 | 8 | |g volume:47 |g year:2020 |g number:6 |g pages:527-542 |g extent:16 |a Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10928-020-09704-1 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211125 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |d 50000 |e 910000PM110903137 |e 910100PM110903137 |e 50000PM110903137 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 3 |y j | ||
| 998 | |g 1076301991 |a Meid, Andreas |m 1076301991:Meid, Andreas |d 910000 |d 910100 |d 50000 |e 910000PM1076301991 |e 910100PM1076301991 |e 50000PM1076301991 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 2 | ||
| 998 | |g 1219325988 |a Wiebe, Sabrina |m 1219325988:Wiebe, Sabrina |d 50000 |e 50000PW1219325988 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1779108338 |e 4007749361 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1779108338","relHost":[{"origin":[{"dateIssuedDisp":"2001-","publisher":"Springer Science + Business Media B.V. ; Kluwer Academic","publisherPlace":"Dordrecht [u.a.] ; New York, NY [u.a.]","dateIssuedKey":"2001"}],"id":{"zdb":["2037307-7"],"issn":["1573-8744"],"eki":["325570183"]},"pubHistory":["Volume 28, issue 1 (February 2001)-"],"title":[{"title":"Journal of pharmacokinetics and pharmacodynamics","title_sort":"Journal of pharmacokinetics and pharmacodynamics"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"part":{"pages":"527-542","year":"2020","volume":"47","extent":"16","issue":"6","text":"47(2020), 6, Seite 527-542"},"disp":"Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activityJournal of pharmacokinetics and pharmacodynamics","physDesc":[{"extent":"Online-Ressource"}],"recId":"325570183","note":["Gesehen am 14.03.25"]}],"note":["Gesehen am 25.11.2021"],"name":{"displayForm":["Sabrina T. Wiebe, Andreas D. Meid, Gerd Mikus"]},"person":[{"family":"Wiebe","given":"Sabrina","role":"aut","roleDisplay":"VerfasserIn","display":"Wiebe, Sabrina"},{"display":"Meid, Andreas","roleDisplay":"VerfasserIn","role":"aut","given":"Andreas","family":"Meid"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Gerd","family":"Mikus","display":"Mikus, Gerd"}],"origin":[{"dateIssuedDisp":"08 August 2020","dateIssuedKey":"2020"}],"id":{"doi":["10.1007/s10928-020-09704-1"],"eki":["1779108338"]},"title":[{"title_sort":"Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity","title":"Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity"}],"physDesc":[{"extent":"16 S."}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a WIEBESABRICOMPOSITEM0820 | ||